The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma

Autor:	Rika Kawasaki, Shigeki Motomura, Sachiya Takemura, Hirotaka Takasaki, Hideyuki Koharazawa, Hirohito Sone, Taisei Suzuki, Maki Hagihara, Kenji Motohashi, Naoto Tomita, Jun Taguchi, Chizuko Hashimoto, Rika Sakai, Etsuko Yamazaki, Jun Takizawa, Shin Fujisawa, Wataru Yamamoto, Takayoshi Tachibana, Katsumichi Fujimaki, Keisuke Kawamoto, Hiroyuki Fujita, Kazuho Miyashita
Rok vydání:	2016
Předmět:	Male Cancer Research Pathology Index (economics) Gastroenterology Antibodies Monoclonal Murine-Derived 0302 clinical medicine immune system diseases Prednisone hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols Medicine Extranodal Involvement Aged 80 and over Hematology Middle Aged Prognosis Treatment Outcome Oncology Vincristine 030220 oncology & carcinogenesis Cohort Rituximab Female Lymphoma Large B-Cell Diffuse medicine.drug Adult medicine.medical_specialty Cyclophosphamide Adolescent 03 medical and health sciences Young Adult Internal medicine Humans Lactate Dehydrogenases Aged Neoplasm Staging business.industry Receptors Interleukin-2 medicine.disease Survival Analysis Lymphoma Doxorubicin business Diffuse large B-cell lymphoma Biomarkers 030215 immunology
Zdroj:	Leukemialymphoma. 57(12)
ISSN:	1029-2403
Popis:	We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p 0.0001). When the patients were divided by age (≤60 years and60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0-1 and1). The SIL index is a simple and objective prognostic indicator in DLBCL.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d4f5acea991f3bd234c3ea72695084e https://pubmed.ncbi.nlm.nih.gov/27686108 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.